Financial Performance - The company's revenue for Q3 2021 reached ¥272,116,595.68, representing a year-over-year increase of 17.48%[5] - Net profit attributable to shareholders was ¥127,276,283.26, up 4.26% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥125,588,217.73, reflecting a 10.17% increase year-over-year[5] - Total operating revenue for the current period reached ¥619,721,426.61, an increase of 26.2% compared to ¥491,058,886.79 in the previous period[30] - Net profit for the current period was ¥266,294,363.50, representing a 19.2% increase from ¥223,376,917.75 in the previous period[33] - The company reported a total profit of ¥320,968,916.49, which is a 20.6% increase from ¥265,996,849.31 in the previous period[33] - Basic earnings per share for the current period were ¥0.5244, compared to ¥0.4376 in the previous period, reflecting a growth of 19.8%[37] Cash Flow - Cash flow from operating activities amounted to ¥242,046,010.16, showing a 26.51% increase from the beginning of the year[5] - Cash flow from operating activities generated ¥564,509,773.24, an increase from ¥457,394,693.03 in the previous period[38] - Operating cash inflow totaled CNY 597,623,360.81, an increase of 22.4% compared to CNY 488,077,643.62 in the previous period[41] - Cash outflow from operating activities was CNY 355,577,350.65, up from CNY 296,750,411.43, resulting in a net cash flow from operating activities of CNY 242,046,010.16, an increase of 26.5%[41] - Cash inflow from investment activities reached CNY 578,541,929.36, compared to CNY 309,978,793.06, marking an increase of 86.6%[41] - Cash outflow from investment activities was CNY 735,139,051.92, significantly higher than CNY 365,238,079.30, leading to a net cash flow from investment activities of CNY -156,597,122.56[41] - Cash flow from financing activities resulted in a net outflow of CNY -89,862,925.67, compared to CNY -94,245,120.00 in the previous period[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,853,615,234.67, a 15.51% increase from the previous year[7] - The company's equity attributable to shareholders increased to ¥1,666,004,937.21, marking a 14.43% rise year-over-year[7] - The total liabilities of the company as of September 30, 2021, were RMB 89,793,384.44, compared to RMB 55,419,690.55 in the previous year[25] - Total liabilities reached ¥123,669,634.97, an increase of 61.5% from ¥76,607,698.67 in the previous period[29] - The total current liabilities were 55,419,690.55, reflecting a decrease from 60,881,547.98[51] - The non-current liabilities totaled 21,188,008.12, down from 25,905,218.01[51] Investments and Expenses - Research and development expenses rose by ¥16,414,616.51, an increase of 36.89%, driven by ongoing investments in existing projects[9] - Research and development expenses increased to ¥60,905,616.89, a rise of 37.0% compared to ¥44,491,000.38 in the previous period[33] - Zhejiang WoWo Biotechnology invested RMB 43.45 million in Shanghai Kaiyi Pharmaceutical Technology Co., Ltd. to support its operational and long-term funding needs[19] - The registered capital of Kaiyi Pharmaceutical increased from RMB 260.107 million to RMB 316.615 million after the investment, with Zhejiang WoWo's ownership rising from 19.905% to 35.021%[19] Other Financial Metrics - The weighted average return on net assets was 8.04%, a decrease of 1.04 percentage points compared to the previous year[5] - The company received government subsidies totaling ¥13,262,221.63 during the reporting period[8] - Deferred income increased to ¥25,035,133.36 from ¥20,630,680.00, indicating a growth of 21.7%[29] - The company reported a cash and cash equivalents balance of CNY 216,616,892.70 at the end of the period, down from CNY 191,638,285.30[44] - The company received CNY 560,000,000.00 from investment recoveries, significantly up from CNY 308,000,000.00[41] - The company paid CNY 170,589,965.13 to employees, an increase from CNY 117,772,149.72, indicating a focus on workforce investment[41] Reporting and Compliance - The report for the third quarter of 2021 was not audited, indicating a potential area for further scrutiny[55] - The company has implemented new leasing standards effective from January 1, 2021, impacting asset and liability recognition[54]

Revenue and Profitability - The company's operating revenue for the reporting period was CNY 347,604,830.93, representing a 33.99% increase compared to CNY 259,428,281.04 in the same period last year[38]. - The net profit attributable to shareholders was CNY 147,316,566.21, up 37.61% from CNY 107,055,199.74 year-on-year[38]. - The net profit after deducting non-recurring gains and losses was CNY 132,813,880.84, reflecting a 26.85% increase from CNY 104,702,220.64 in the previous year[38]. - The net cash flow from operating activities was CNY 141,509,362.09, which is a 16.68% increase compared to CNY 121,281,305.63 in the same period last year[38]. - The growth in revenue and net profit is primarily due to the low base from the impact of COVID-19 in the first half of 2020[59]. Product Development and Regulatory Approvals - The new product "Artemisia Flower Pollen Allergen Sublingual Drops" received regulatory approval on January 30, 2021, but large-scale sales will take time to develop[12]. - The company launched a new product, the "Artemisia Flower Pollen Sublingual Drops," which received approval from the National Medical Products Administration on January 30, 2021[50]. - The company has received approval for its sublingual allergen immunotherapy products, including "Dust Mite Drops" and "Artemisia Pollen Sublingual Drops," enhancing its product line and market competitiveness[66]. - The development of new drugs is subject to lengthy regulatory processes, which may delay market entry and affect competitiveness[15]. - The company acknowledges risks in new drug development due to stringent regulatory requirements, which can prolong the time from research to market[110]. Market Strategy and Risks - The company plans to strengthen the promotion of new products to accelerate their market entry and reduce reliance on existing products[12]. - The company aims to enhance hospital coverage and academic marketing to adapt to market changes and maintain revenue stability[10]. - The company is facing risks from price reductions in the pharmaceutical industry due to healthcare cost control measures[8]. - The company is experiencing a trend of price reductions in pharmaceuticals, which may impact sales in certain regions, prompting a potential strategy to maintain price stability by possibly forgoing sales in some areas[109]. - The company plans to enhance the promotion of existing products to mitigate external factors affecting sustainable growth[110]. Financial Position and Investments - The total assets at the end of the reporting period were CNY 1,672,994,248.84, an increase of 4.25% from CNY 1,604,755,527.30 at the end of the previous year[38]. - The net assets attributable to shareholders were CNY 1,519,448,460.30, up 4.36% from CNY 1,455,908,680.17 at the end of the previous year[38]. - The company received government subsidies amounting to CNY 12,726,412.52 during the reporting period[45]. - The company completed the acquisition of a stake in Shanghai Kaiyi Pharmaceutical Technology Co., increasing its ownership to 35.021%, making it an associate company[67]. - The company has invested CNY 285.96 million in the "Allergen Point Injection Liquid Technical Transformation Project" using raised funds[93]. Research and Development - The company has established a robust R&D team and a fully autonomous R&D chain to enhance its product development capabilities[57]. - Research and development investment totaled ¥44,805,794.93, accounting for 12.89% of operating income, with stem cell research receiving ¥22,053,934.57 and natural medicine research receiving ¥4,860,006.34[72]. - The company emphasizes continuous R&D and innovation to maintain its competitive edge in the pharmaceutical market[68]. - The company is actively expanding into the natural medicine sector, focusing on discovering new structures and molecules to combat antibiotic-resistant bacteria[62]. - The company is in the process of developing new antibiotics to address the urgent need for treatments against "superbugs," leveraging China's rich biological resources[62]. Environmental and Social Responsibility - The company has established environmental protection measures and complies with relevant laws, ensuring that pollution control facilities are operational[125]. - The company promotes a "green office" initiative, utilizing electronic document management to save paper and implementing energy-saving practices in the workplace[129]. - The company actively engages in social responsibility initiatives, including supporting impoverished students and families through charitable actions[132]. - The company has developed an emergency response plan for environmental incidents, enhancing its management of potential environmental risks[125]. - The company achieved energy management system certification in May 2021, effectively reducing energy consumption and improving energy efficiency[126]. Governance and Compliance - The company maintains a robust governance structure to protect shareholder rights, ensuring accurate and timely information disclosure[127]. - There were no instances of non-operating fund occupation by controlling shareholders or related parties during the reporting period[140]. - The company reported no violations regarding external guarantees during the reporting period[141]. - The company did not undergo an audit for the semi-annual financial report[142]. - The company has no significant guarantees during the reporting period[162].

Financial Performance - The company's revenue for Q1 2021 was CNY 164,654,385.39, representing a 49.31% increase compared to CNY 110,275,663.26 in the same period last year[8]. - Net profit attributable to shareholders was CNY 70,454,208.66, a 70.31% increase from CNY 41,368,706.64 year-over-year[8]. - The company achieved operating revenue of CNY 164,654,385.39, an increase of 49.31% compared to the same period last year[26]. - The net profit attributable to shareholders reached CNY 70,454,208.66, reflecting a growth of 70.31% year-on-year[26]. - The company reported a total profit of ¥80,882,386.26 for the current period, up from ¥47,975,664.52 in the previous period, marking an increase of around 68.5%[81]. - The company reported a total comprehensive income of ¥67,728,189.15 for the current period, compared to ¥40,235,491.85 in the previous period, reflecting a growth of approximately 68.3%[84]. Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 99,954,766.48, up 47.60% from CNY 67,719,778.94 in the previous year[8]. - Cash inflow from operating activities totaled ¥208,110,123.73, up from ¥160,933,608.23, reflecting a growth of approximately 29.3%[96]. - Cash and cash equivalents increased by CNY 100,408,803.99, a significant rise of 182.66% due to improved cash flow from operations and investments[25]. - Cash and cash equivalents at the end of the period were ¥376,413,028.97, up from ¥204,794,812.25, reflecting an increase of approximately 83.5%[98]. - The company experienced a net increase in cash and cash equivalents of ¥155,378,384.69, compared to ¥54,969,580.70 in the previous period, showing strong liquidity growth[98]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,690,191,869.39, reflecting a 5.32% increase from CNY 1,604,755,527.30 at the end of the previous year[8]. - Current liabilities rose to CNY 64,949,417.92, compared to CNY 55,419,690.55, indicating an increase of approximately 17.36%[63]. - Total liabilities reached CNY 94,315,851.61, up from CNY 76,607,698.67, marking a growth of around 23.14%[63]. - Owner's equity increased to CNY 1,595,876,017.78 from CNY 1,528,147,828.63, showing a growth of about 4.42%[66]. - Non-current assets totaled CNY 456,869,820.84, an increase from CNY 433,817,332.64, reflecting a growth of about 5.73%[66]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,588[12]. - The largest shareholder, Zhejiang Wowo Management Consulting Co., Ltd., held 38.86% of the shares[13]. Research and Development - Research and development expenses rose by CNY 9,229,096.19, an increase of 84.50%, driven by enhanced investment in stem cell and natural medicine research[24]. - The newly developed product, "Artemisia Annua Pollen Allergen Sublingual Drops," received regulatory approval on January 30, 2021, but large-scale sales will take time, highlighting ongoing reliance on existing products[34]. - The company plans to enhance the promotion of "Artemisia Annua Pollen Allergen Sublingual Drops" to expedite its market entry and reduce reliance on existing products[34]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 10,083,635.66 during the reporting period[8]. - The company received government subsidies related to daily operations, resulting in other income increasing by CNY 10,200,362.77, a staggering growth of 568,632.81%[24]. Risks and Challenges - The company faces risks related to industry policy changes and potential price reductions in drug tenders, which may impact future performance[29]. - The company faces risks in new drug development due to stringent regulatory requirements, which can delay market entry and affect competitiveness if clinical trials do not meet expectations[35]. - The company has faced challenges in ensuring new drugs gain market acceptance, which could impact sales volume if they lack competitiveness[35]. Investment and Projects - The company has received approval from the China Securities Regulatory Commission for a specific stock issuance to fund projects, including a natural medicine utilization base and an animal testing center[36]. - The company terminated the "Marketing Network Expansion and Information Technology Construction Project" and will permanently supplement the remaining raised funds of CNY 2,888.52 million into working capital[48]. - The "Annual Production of 3 Million Dust Mite Drops Technology Renovation Project" has an actual investment of CNY 11,427.52 million, achieving 97.92% of the planned investment[45]. - The "Allergen Research and Development Center Technology Renovation Project" has an actual investment of CNY 4,429.32 million, achieving 94.95% of the planned investment[45].

Revenue and Profit Performance - During the reporting period, the company's sales revenue and net profit experienced a slight decline due to the impact of the COVID-19 pandemic[11]. - The company's operating revenue for 2020 was approximately ¥636.21 million, a decrease of 0.49% compared to ¥639.35 million in 2019[32]. - The net profit attributable to shareholders for 2020 was approximately ¥278.45 million, down 6.65% from ¥298.30 million in 2019[32]. - The net profit after deducting non-recurring gains and losses was approximately ¥261.47 million, a decrease of 11.14% compared to ¥294.24 million in 2019[32]. - The net profit for the fourth quarter of 2020 was approximately ¥49.32 million, compared to ¥122.08 million in the third quarter[35]. - The total net profit for the year included non-recurring gains of approximately ¥16.97 million, significantly higher than the previous year's ¥4.06 million[38]. - The company's revenue for the reporting period was approximately ¥636.21 million, a decrease of 0.49% compared to the previous year[70]. - Revenue from pharmaceutical manufacturing was ¥633,418,932.57, accounting for 99.56% of total revenue, with a slight decrease of 0.17% year-over-year[79]. Product Development and R&D - The new product "Artemisia Flower Pollen Allergen Sublingual Drops" received regulatory approval on January 30, 2021, but large-scale sales will take time[12]. - The company is committed to accelerating the R&D process for new drugs to minimize development risks and enhance market competitiveness[16]. - The total R&D investment for the year was ¥78,638,900, accounting for 12.36% of operating revenue[56]. - The company has developed a proprietary stem cell culture system, enhancing its capabilities in stem cell research and production[51]. - The company is advancing multiple products in the allergy treatment field, with several in Phase III clinical trials[62]. - The company is entering significant medical product fields such as cell therapy, natural medicine, and medical artificial intelligence, aiming to form new product clusters in 2-3 pharmaceutical areas over the next decade[185]. - The company is focused on improving corporate governance structures and enhancing information disclosure quality to ensure compliance with legal requirements[188]. Financial Management and Cash Flow - The net cash flow from operating activities increased by 10.00% to approximately ¥256.22 million from ¥232.93 million in 2019[32]. - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥71.21 million, a 122.95% improvement compared to the previous year[70]. - The net cash flow from investment activities improved significantly by 85.05%, resulting in a net outflow of ¥90,737,666.44 in 2020, compared to a much larger outflow in 2019[95]. - The company's total assets at the end of 2020 were ¥1.60 billion, an increase of 12.36% from ¥1.43 billion at the end of 2019[32]. - The proportion of trading financial assets increased to 19.13% of total assets, amounting to ¥307,033,893.91, due to increased investments in bank wealth management products[99]. Market Strategy and Sales - The company will strengthen its marketing efforts for existing leading products to mitigate external impacts and ensure sustainable growth[11]. - The company is focusing on academic marketing to enhance its market presence in the allergy treatment sector[46]. - The company aims to improve human quality of life and extend healthy lifespan through innovative pharmaceutical products, aspiring to become an international pharmaceutical industry leader[181]. - To expand market share and enhance brand influence, the company will intensify academic promotion efforts and participate in domestic and international academic conferences[187]. - The company is actively pursuing collaborations with hospitals for academic promotion and has established a new subsidiary focused on the sales of quasi-pharmaceutical functional products[67]. Regulatory Environment and Risks - Regulatory changes in the pharmaceutical industry are tightening, requiring companies to adapt to new quality management standards[10]. - The regulatory environment for the biopharmaceutical industry in China is tightening, impacting R&D, production, and sales[47]. - The pharmaceutical industry is facing increasing regulatory scrutiny, and the company will monitor policy changes to mitigate operational risks[191]. - The company acknowledges risks associated with new drug development, including lengthy regulatory processes and potential market acceptance issues[192]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 1.6 RMB per 10 shares, based on a total of 523,584,000 shares[16]. - The total cash dividend amount for the year was RMB 83,773,440, which accounted for 100% of the distributable profit[200]. - The company distributed cash dividends of RMB 1.80 per 10 shares, totaling RMB 94,245,120 for the year 2019[199]. - The cash dividend policy was strictly followed according to the company's articles of association[199].

Financial Performance - Operating revenue for the reporting period was ¥231,630,605.75, reflecting a year-on-year growth of 2.64%[8] - Net profit attributable to shareholders was ¥122,075,459.45, representing a 5.14% increase compared to the same period last year[8] - Basic earnings per share for the reporting period were ¥0.2332, up by 5.19% compared to the previous year[8] - The company reported a net profit of approximately ¥629.19 million, a significant increase from ¥494.30 million, reflecting a growth of around 27% year-over-year[46] - Net profit for the current period was 119,313,074.75, compared to 114,131,251.78 in the previous period, showing an increase of about 4.8%[58] - The total profit for the current period is 155,518,119.24, compared to 142,673,882.50 in the previous period, indicating an increase of around 8.9%[62] - The net profit for the current period is ¥132,570,783.99, up from ¥121,649,888.13 in the previous period, representing an increase of about 9.9%[62] - Net profit for the current period is ¥249,385,642.81, a decrease of 2.67% compared to ¥255,072,647.21 in the previous period[77] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,562,152,170.56, an increase of 9.38% compared to the end of the previous year[8] - Current assets totaled approximately ¥1.15 billion, up from ¥1.05 billion, indicating an increase of around 10% year-over-year[37] - Total liabilities amounted to approximately ¥81.07 million, compared to ¥76.25 million, marking an increase of around 6%[43] - Total liabilities increased to 72,044,126.91 from 66,931,968.97, marking an increase of about 7.5%[56] - Total assets amounted to 1,444,504,620.60, up from 1,284,251,939.85, indicating an increase of approximately 12.5%[56] - The company's total equity attributable to shareholders reached approximately ¥1.41 billion, up from ¥1.27 billion, indicating a growth of about 10%[46] Cash Flow - The net cash flow from operating activities was ¥70,045,926.56, showing a significant increase of 29.69% year-on-year[8] - Net cash flow from financing activities decreased by ¥158,025,120.00, down 247.77% year-on-year, mainly due to reduced cash received from minority shareholder investments in subsidiaries[23] - Net increase in cash and cash equivalents decreased by ¥124,004,235.10, down 74.78% year-on-year, due to a decrease in cash flow from financing activities and an increase in cash flow from operating activities[23] - Cash flow from operating activities generated a net amount of ¥191,327,232.19, an increase from ¥157,551,183.19 in the previous period[80] - Cash and cash equivalents at the end of the period totaled ¥191,638,285.30, down from ¥625,860,419.05 in the previous period[82] Research and Development - R&D expenses increased by ¥18,334,042.06, a growth of 70.09% year-on-year, mainly due to continued investment in existing R&D projects such as stem cells[22] - Research and development expenses rose to 19,595,994.02 from 12,102,332.46, representing an increase of approximately 61.8%[56] - Research and development expenses increased to ¥16,156,709.96, up 49.73% from ¥10,829,800.92 in the previous period[74] - The company plans to continue expanding its R&D efforts and product offerings in the future[22] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,485, with the largest shareholder holding 38.86% of the shares[11] - The company did not engage in any repurchase transactions during the reporting period[14] - There are no non-operating fund occupations by controlling shareholders and their related parties during the reporting period[30] Government Subsidies - The company received government subsidies amounting to ¥10,244,888.84 during the reporting period, primarily from the Huzhou Mogan Mountain High-tech Industrial Development Zone[10] - Non-operating income increased by ¥6,771,819.20, up 189.60% year-on-year, mainly due to an increase in government subsidies received[22] Financial Standards and Compliance - The company has no violations of external guarantees during the reporting period[29] - The company has implemented new revenue and leasing standards starting from 2020, necessitating adjustments in financial reporting[90] - The company executed the new revenue recognition standards starting January 1, 2020[100]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 259,428,281.04, a decrease of 5.43% compared to CNY 274,337,272.82 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was CNY 107,055,199.74, down 17.95% from CNY 130,478,340.23 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was CNY 104,702,220.64, a decrease of 17.88% compared to CNY 127,500,058.62 in the previous year[24]. - The basic earnings per share were CNY 0.2045, down 17.94% from CNY 0.2492 in the previous year[24]. - The company's operating revenue for the reporting period was ¥259,428,281.04, a decrease of 5.43% compared to ¥274,337,272.82 in the same period last year[53]. - Net profit attributable to shareholders was 107.06 million CNY, down 17.95% year-on-year, while the net profit after deducting non-recurring gains and losses was 104.70 million CNY, a decline of 17.88%[45]. Cash Flow and Assets - The net cash flow from operating activities increased by 17.14% to CNY 121,281,305.63, compared to CNY 103,539,335.95 in the same period last year[24]. - The company's total assets at the end of the reporting period were ¥1,426,000,000, with cash and cash equivalents accounting for 54.51% of total assets[58]. - The company's total current assets were CNY 1,025,465,952.29, down from CNY 1,050,003,417.09 at the end of 2019, indicating a decrease of approximately 2.3%[186]. - Cash and cash equivalents increased to CNY 776,997,787.67 from CNY 750,771,219.24, reflecting a growth of about 3.5%[184]. - Total liabilities decreased to CNY 63,530,434.61 from CNY 76,252,963.83, a reduction of approximately 16.7%[190]. Research and Development - The company invested 31.13 million yuan in R&D, accounting for 12.00% of operating revenue[39]. - Research and development expenses increased by 77.13% to ¥24,895,006.36 from ¥14,054,625.86 in the previous year, reflecting a continued investment in R&D projects[53]. - The company has developed self-researched culture media and cryopreservation solutions, transitioning from traditional imports to high-quality domestic and self-developed materials[45]. - The company is in the technical review stage for its new product, "Artemisia Flower Pollen Sublingual Drops," which is expected to expand the market for sublingual immunotherapy[34]. Risk Factors - The company faces risks related to industry policies, bidding price reductions, and concentration of leading products[7]. - The company emphasizes the importance of risk awareness regarding future plans and goals[6]. - New drug development poses risks due to long cycles and high investment, with potential market misalignment impacting operations[89]. - The COVID-19 pandemic has affected production, R&D, and market promotion, with ongoing adjustments to business strategies to enhance competitiveness[92]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[7]. - The actual controller and shareholders have adhered to their commitments during the reporting period, with no violations reported[97]. - Shareholders are restricted from transferring or entrusting their shares for 36 months post-listing, with specific conditions for share reduction thereafter[100]. - The company reported a stock reduction of 440,000 shares, accounting for 0.27% of total shares, at an average price of 39.70 CNY per share, violating commitments made during the IPO[110]. Subsidiaries and Investments - The company established Zhejiang Wuwu Natural Medicine Co., Ltd. with a registered capital of 50 million CNY in May 2020 to focus on the development of natural medicines[45]. - The company has established three new subsidiaries, which had no significant impact on overall operations and performance[86]. - The total amount of raised funds is CNY 192.38 million, with CNY 3.15 million utilized during the reporting period[68]. Compliance and Governance - The company has not experienced any major litigation or arbitration matters during the reporting period[113]. - There were no significant penalties or rectification situations reported during the period[116]. - The company did not engage in any related party transactions during the reporting period[118].

证券代码：300357 证券简称：我武生物 公告编号：2020-033 号 浙江我武生物科技股份有限公司 关于参加浙江辖区上市公司投资者网上集体接待日活 动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，使广大投资者能更深入全面地了解公司 情况，浙江我武生物科技股份有限公司（以下简称"公司"）将参加由浙江证监 局指导、浙江上市公司协会与深圳市全景网络有限公司共同举办的"凝心聚力 共 克时艰"辖区上市公司投资者网上集体接待日主题活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景•路演天下"网站（http://rs.p5w.net）参与本 次投资者网上集体接待日活动。网上互动交流时间为2020年5月15日（星期五） 下午15:00-17:00。 届时公司部分高级管理人员（具体以当天出席为准）将通过网络在线交流方 式与投资者进行沟通交流。 欢迎广大投资者积极参与。 特此公告。 浙江我武生物科技股份有限公司董事会 2020 年 5 月 11 日 ...

Financial Performance - Total revenue for Q1 2020 was ¥110,275,663.26, a decrease of 20.14% compared to ¥138,084,397.75 in the same period last year[8] - Net profit attributable to shareholders was ¥41,368,706.64, down 37.45% from ¥66,137,709.53 year-on-year[8] - Net profit excluding non-recurring gains and losses was ¥40,151,830.51, a decrease of 38.21% from ¥64,976,342.53 in the previous year[8] - Basic earnings per share were ¥0.0790, down 37.45% from ¥0.1263 year-on-year[8] - Operating profit decreased by CNY 30,284,720.52, a decline of 39.31% primarily due to reduced revenue and increased R&D costs[23] - Net profit for the period was CNY 40,229,000.00, down from CNY 65,474,000.00 in the previous period, indicating a decline of 38.7%[72] - The total profit for the current period was 53,492,341.55 CNY, down from 79,091,801.55 CNY, reflecting a decrease of approximately 32.5%[78] Cash Flow - Operating cash flow for the period was ¥67,719,778.94, an increase of 39.98% compared to ¥48,377,037.23 in the same period last year[8] - The net cash flow from operating activities increased by CNY 19,342,741.71, up 39.98% due to higher cash receipts from sales[24] - The cash inflow from operating activities totaled 160,933,608.23 CNY, compared to 144,418,910.08 CNY in the previous period, indicating an increase of approximately 11.5%[82] - The ending balance of cash and cash equivalents was 204,794,812.25, up from 149,825,231.55 at the beginning of the period[88] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,451,910,687.75, an increase of 1.66% from ¥1,428,210,902.69 at the end of the previous year[8] - The total current assets as of March 31, 2020, amount to 1,059.60 million yuan, compared to 1,050.00 million yuan at the end of 2019[51] - The total liabilities as of March 31, 2020, are 59.72 million yuan, down from 76.25 million yuan at the end of 2019[57] - The total equity increased to CNY 1,263,065,882.09 from CNY 1,217,319,970.88, representing a growth of 3.8%[67] Research and Development - R&D expenses increased by CNY 4,482,209.82, representing a growth of 69.61% due to higher salaries and depreciation[23] - Research and development expenses increased significantly to CNY 10,921,550.21, compared to CNY 6,439,340.39 in the previous period, reflecting a growth of 69.3%[72] - The company is in the technical review phase for the registration of a new sublingual drop product for treating pollen allergies, which is expected to enhance product lines and market competitiveness[27] - The company has several ongoing clinical trials, including a Phase III trial for a dust mite drop product, aimed at expanding the patient population and improving market competitiveness[27] Shareholder Information - The top shareholder, Zhejiang Wowo Management Consulting Co., Ltd., holds 38.86% of the shares[13] - The total number of ordinary shareholders at the end of the reporting period was 22,508[13] - The company has committed to a share reduction plan, allowing for a maximum of 1% of total shares to be sold through centralized bidding within one month after the lock-up period[37] - The company has not completed the commitments made by major shareholders regarding stock reduction, with specific reasons outlined for non-compliance[37] Fundraising and Investments - The company reported a total fundraising amount of 19,238.41 million yuan, with 315.00 million yuan invested in the current quarter[38] - The company has not changed the investment projects for the raised funds, maintaining a commitment to the original investment plan[40] - The marketing network expansion and information technology construction project has not met planned progress due to changes in market conditions and the decision to halt further investments in office properties[40] - The company decided to terminate the flow of funds for the marketing network expansion project, reallocating the remaining funds to supplement working capital[40] Impact of COVID-19 - The company faced significant impacts from the COVID-19 pandemic on production, technology development, and market promotion, with ongoing risks from overseas outbreaks[32] - The company plans to address the ongoing risks from the pandemic by monitoring the situation and adjusting operations accordingly[32]

Financial Performance - The company's operating revenue for 2019 was CNY 639,352,853.82, representing a 27.68% increase from CNY 500,744,692.07 in 2018[22]. - The net profit attributable to shareholders of the listed company for 2019 was CNY 298,296,581.56, up 28.09% from CNY 232,884,097.51 in 2018[22]. - The net profit after deducting non-recurring gains and losses was CNY 294,236,870.24, reflecting a 30.85% increase compared to CNY 224,864,128.66 in 2018[22]. - The net cash flow from operating activities was CNY 232,925,579.31, which is a 12.82% increase from CNY 206,452,525.31 in 2018[22]. - The total assets at the end of 2019 amounted to CNY 1,428,210,902.69, a 35.01% increase from CNY 1,057,892,508.68 at the end of 2018[22]. - The net assets attributable to shareholders of the listed company were CNY 1,270,995,838.35, up 31.10% from CNY 969,517,290.46 at the end of 2018[22]. - The basic earnings per share for 2019 was CNY 0.5697, an increase of 28.08% from CNY 0.4448 in 2018[22]. - The diluted earnings per share also stood at CNY 0.5697, reflecting the same growth of 28.08% compared to CNY 0.4448 in 2018[22]. - The weighted average return on equity for 2019 was 26.04%, slightly down from 26.63% in 2018[22]. Research and Development - The total R&D investment for the year was 68.74 million yuan, accounting for 10.75% of operating revenue, with 40.10% of R&D expenses capitalized[46]. - The company holds a total of 16 valid patents, including 13 domestic invention patents and 3 international patents[46]. - The company is focusing on the anti-aging and regenerative medicine sectors through its subsidiary, Shanghai Iwu Stem Cell Technology Co., Ltd.[34]. - The company is actively expanding its product line in the field of desensitization diagnosis and treatment, with ongoing clinical trials for multiple products[46]. - The company’s R&D expenses increased by 205.46% to ¥41,171,088.98, primarily due to intensified efforts in stem cell project development[67]. - The company completed the Phase III clinical trial for "Artemisia annua powder sublingual drops" for treating allergic rhinitis, with a summary report formed[1]. - The company announced a cash dividend of RMB 2.50 per share and a bonus issue of 8 shares for every 10 shares held, totaling a cash distribution of RMB 72.72 million and increasing total shares to 523.58 million[1]. Market Position and Product Development - The company has expanded its product coverage to over 30 provinces, cities, and autonomous regions in China[34]. - The new product "Artemisia annua pollen sublingual drops" has completed phase III clinical trials and a drug registration application has been submitted[34]. - The company maintains a leading position in the dust mite desensitization drug market, with its product "Dust Mite Drops" ranked first since 2011[38]. - The dust mite drop product accounted for 98.65% of total revenue, with sales reaching ¥630,742,058.06, up 27.50% from the previous year[55]. - The company is focusing on developing complementary products in the field of allergic diseases to maintain its competitive advantage[102]. Financial Management - The cost of sales decreased by 19.87% to ¥22,852,631.56 from ¥28,518,185.46, indicating improved cost management[49]. - The company reported a significant increase in financial income, with financial expenses decreasing by 115.28% to -¥24,064,368.34, attributed to a rise in bank interest income[49]. - The company’s tax expenses increased by 29.13% to ¥53,095,990.53, reflecting higher profitability[49]. - The company’s financing activities generated a net cash inflow of ¥63,780,000.00, a turnaround from a net outflow of -¥64,640,000.00 in the previous year, due to increased cash from minority shareholder investments[49]. - The company’s total operating costs were ¥639,352,853.82, with a year-on-year decrease of 19.87%[63]. Shareholder Returns - The company distributed cash dividends of RMB 72,720,000, with a payout of RMB 2.50 per 10 shares, and issued 232,704,000 bonus shares, increasing total share capital to 523,584,000 shares[114]. - The cash dividend for 2019 represents 31.59% of the net profit attributable to ordinary shareholders, which was RMB 298,296,581.56[118]. - The remaining undistributed profit after the dividend payout in 2019 is RMB 422,173,160.08, retained for operational needs[118]. - The company has consistently increased its total share capital through stock dividends, with an increase to 523,584,000 shares in 2019 from 290,880,000 shares in 2018[118]. Corporate Governance and Compliance - The company is committed to improving corporate governance and internal control systems to ensure legal and efficient operations[105]. - The company has adhered to its commitments regarding shareholding restrictions and has not violated any promises during the reporting period[119]. - The company has not encountered any bankruptcy restructuring matters during the reporting period[142]. - The company has maintained a continuous audit relationship with Ernst & Young Huaming for 5 years, with the current audit fee set at 700,000 CNY[141]. - The company has not reported any changes in the ownership and control relationship with the actual controlling shareholder during the reporting period[199]. Risks and Challenges - The company faces industry policy risks due to ongoing healthcare reforms, which may impact drug development, production, and sales, leading to increased competition and pressure on sales[108]. - The company acknowledges risks related to new drug development, including long cycles and high investment, which may affect operational stability if market needs are not met[110]. - The company anticipates challenges from price reductions in drug tenders, which may impact long-term sales strategies and overall performance[108].

证券代码：300357 证券简称：我武生物 公告编码：2019-059 号 浙江我武生物科技股份有限公司 关于参加浙江辖区上市公司网上投资者集体接待日活 动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，使广大投资者能更深入全面地了解 公司情况，浙江我武生物科技股份有限公司（以下简称"公司"）将参加由浙 江证监局指导、浙江上市公司协会与深圳市全景网络有限公司共同举办的 "沟通促发展 理性共成长"辖区上市公司投资者集体接待日活动，现将有 关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供 的网上平台采取网络远程的方式进行，投资者可以登录"全景•路演天下" （http://rs.p5w.net）参与本次投资者网上集体接待日活动，网上互动交流时 间为2019年11月5日（星期二）下午15:30-17:00。 届时公司董事会秘书、财务总监和相关管理人员将通过网络在线交流方 式与投资者进行沟通交流。（如有特殊情况，参与人员会有调整） 欢迎广大投资者积极参与。 特此公告。 浙江我武生物科技股份有限公司董事 ...